ABL1
Tyrosine-protein kinase ABL1
As of the edition of 20 October 2026, ABL1 (tyrosine-protein kinase ABL1, UniProt P00519) has 21 drugs tested at it and 26 companies on the list, 7 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00519
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 85
- Disease areas
- Cancer; Blood and lymph; Immune system; Digestive system; Lungs and airways; Skin and connective tissue; Nervous system; Urinary and reproductive
- Registered trials of its drugs
- 1,118
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 7 |
| Active | 3 |
| Went quiet | 3 |
| Stopped | 6 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 21 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Imatinib | Marketed | Phase 4 | none listed |
| Dasatinib anhydrous | Marketed | Phase 4 | Ended 2026 |
| Nilotinib | Marketed | Phase 4 | Ends 2032 |
| Ponatinib | Marketed | Phase 3 | Ends 2033 |
| Bosutinib | Marketed | Phase 4 | Ends 2031 |
| Asciminib | Marketed | Phase 4 | Ends 2040 |
| Umbralisib | Withdrawn from market | Phase 3 | Ends 2035 |
| Olverembatinib | Active | Phase 3 | none listed |
| Flumatinib | Stopped | Phase 4 | none listed |
| Ruserontinib | Status not established | Phase 3 | none listed |
| Radotinib | Marketed | Phase 3 | none listed |
| Vodobatinib | Stopped | Phase 2 | none listed |
12 of 21 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Route B | 3 |
| Engaged | 9 |
| Undetermined | 7 |
| Total on the list | 26 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route B |
| Pfizer | Route B |
| TG Therapeutics | Route A |
The other 23 companies at ABL1
In the product26 companies in all; 23 are not named here, and no score is.
See the 26 companies at ABL1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.